ABBOTT LABORATORIES - 8-K Filing

Abbott Laboratories reports Q3 2026 sales growth of 14.5% and reaffirms full-year adjusted EPS guidance. (Items: 2.02 Results of Operations and Financial ConditionOn October 21, 2026, Abbott Laboratories announced its results of operations for the third quart, 9.01 Financial Statements and ExhibitsExhibit No)

SEC EDGAR · October 21, 2026, 11:37 UTC

Tickers: $ABT

Read the full article at SEC EDGAR

Part of the story JOHNSON & JOHNSON - 8-K Filing (37 articles)

More Regulatory news

Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Dare Bioscience, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
NEXGEL, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
TEREX CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Victory Capital Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:59 UTC
Nano Dimension Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 13:59 UTC
M-tron Industries, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:56 UTC
M-tron Industries, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:55 UTC